Oncology
Oncology
Breast cancer
One in 8 women in the EU will develop breast cancer before the age of 85. This disease is associated with a great economic cost. In fact, in 2010 it was estimated at more than €15 billion in Europe. About 46% of the breast cancer cost is spent on treatments and drugs1 that are selected by general guidelines and may not be efficient for a specific patient.
1 in 8
women will develope it
>€ 15 billion cost
Drugs selected by general
guidelines
Led by IBM, this pilot supports precision medicine to improve accuracy in diagnosis and propose treatments that are more targeted, less toxic and therefore better tolerated.
Why a big data approach is needed
Prediction by big data analytics can support the physicians on their decision for the personalized optimal treatment for the patient.
Leader
Participants
Publications
Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy
10/08/2022
Rabinovici-Cohen, S.; Fernández, X.M.; Grandal Rejo, B.; Hexter, E.; Hijano Cubelos, O.; Pajula, J.; Pölönen, H.; Reyal, F.; Rosen-Zvi, M. Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy. Cancers 2022, 14, 3848. https://doi.org/10.3390/cancers14163848
Early prediction of metastasis in women with locally advanced breast cancer
04/04/2022
Simona Rabinovici-Cohen, Tal Tlusty, Xosé M. Fernández, Beatriz Grandal Rejo, “Early prediction of metastasis in women with locally advanced breast cancer,” Proc. SPIE 12033, Medical Imaging 2022: Computer-Aided Diagnosis, 120330F (4 April 2022); https://doi.org/10.1117/12.2613169
Prediction of Five-Year Breast Cancer Recurrence in Women Treated with Neoadjuvant Chemotherapy
19/10/2021
Rabinovici-Cohen S., Fernández X., Grandal Rejo B., Hexter E., Hijano Cubelos O., Pajula J., Pölönen H., Reyal F., Rosen-Zvi M., “Prediction of Five-Year Breast Cancer Recurrence in Women Treated with Neoadjuvant Chemotherapy”, AMIA Annual Symposium Proceedings 2021.
FuseMedML Open Source: https://github.com/IBM/fuse-med-ml
17/08/2021
@misc{https://doi.org/10.5281/zenodo.5146491,
doi = {10.5281/ZENODO.5146491},
url = {https://zenodo.org/record/5146491},
author = {IBM Research, Haifa},
title = {FuseMedML: https://github.com/IBM/fuse-med-ml},
publisher = {Zenodo},
year = {2021},
copyright = {Apache License 2.0}
}
Multimodal Prediction of Breast Cancer Relapse Prior to Neoadjuvant Chemotherapy Treatment
10/02/2021
Rabinovici-Cohen S., Abutbul A., Fernández X.M., Hijano Cubelos O., Perek S., Tlusty T. (2020) Multimodal Prediction of Breast Cancer Relapse Prior to Neoadjuvant Chemotherapy Treatment. In: Rekik I., Adeli E., Park S.H., Valdés Hernández M..C. (eds) Predictive Intelligence in Medicine. PRIME 2020. Lecture Notes in Computer Science, vol 12329. Springer, Cham. https://doi.org/10.1007/978-3-030-59354-4_18
Radiomics for predicting response to neoadjuvant chemotherapy treatment in breast cancer
15/04/2020
Simona Rabinovici-Cohen, Tal Tlusty, Ami Abutbul, Kari Antila, Xosé Fernandez, Beatriz Grandal Rejo, Efrat Hexter, Oliver Hijano Cubelos, Abed Khateeb, Juha Pajula, and Shaked Perek “Radiomics for predicting response to neoadjuvant chemotherapy treatment in breast cancer”, Proc. SPIE 11318, Medical Imaging 2020: Imaging Informatics for Healthcare, Research, and Applications, 113181B (2 March 2020); https://doi.org/10.1117/12.2551374
1 Source: Capri S., Russo A.: Cost of breast cancer based on real-world data: a cancer registry study in Italy, BMC health Services Research, 17(1):84, 2017.